You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. Prostate cancer discovery opens door to more tailored treatments
- 2. Recent advances in therapeutic use of transforming growth factor-beta inhibitors in cancer and fibrosis
- 3. Dual roles of methylglyoxal in cancer
- 4. Prostate cancer, race and the need for tests | Letters
- 5. LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
- 6. Halozyme sues Merck; FDA blames cuts for Vanda delay
- 7. Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
- 8. Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
- 9. Rgenta Therapeutics Presents Preclinical Data on RGT-61159, a Potent, Selective Oral Small Molecule Inhibitor of MYB, Demonstrating Robust Anti-Tumor Activity in Several Monotherapy Models of AML and Synergistic Activity when Combined with Standard of Care for AML
- 10. Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab
Last updated at 16:17 GMT
Hot News Makers
Health/Pharma Companies
-
29392.61
-
4700.81
-
3695.83
-
2168.08
-
926.23
-
798.23
-
651.22
-
561.56
-
399.22
-
347.44
Drugs, Treatments, Trials
-
73134.00
-
8127.24
-
4844.63
-
2711.24
-
1756.89
-
1664.26
-
885.80
-
492.98
-
476.97
-
454.36
Last updated at 16:10 GMT
